



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: **0 653 205 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: **95101762.3**

(51) Int. Cl.⁶: **A61K 9/72, A61K 31/58**

(22) Date of filing: **08.06.92**

This application was filed on 10 - 02 - 1995 as a divisional application to the application mentioned under INID code 60.

(30) Priority: **10.06.91 US 712789**

(43) Date of publication of application:
17.05.95 Bulletin 95/20

(60) Publication number of the earlier application in accordance with Art.76 EPC: **0 587 790**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IT LI LU MC
NL PT SE**

(71) Applicant: **SCHERING CORPORATION**
2000 Galloping Hill Road
Kenilworth,
New Jersey 07033-0530 (US)

(72) Inventor: **Fassberg, Julianne**
175 W.12th Street
New York NY 10011 (US)
Inventor: **Chaudry, Imtiaz A.**
18 Rose Avenue
North Caldwell NY 07006 (US)
Inventor: **Sequeira, Joel A.**
18 Stuyvesant Oval
New York NY 10009 (US)
Inventor: **Kopcha, Michael**
141 Wycott Way West
East Brunswick NY 08816 (US)

(74) Representative: **Schlich, George William et al**
Mathys & Squire
100 Grays Inn Road
London WC1X 8AL (GB)

(54) **Non-chlorofluorocarbon aerosol formulations.**

(57) An aerosol formulation contains mometasone furoate and, as propellant, 1,1,1,2-tetrafluoroethane and is suitable for treating asthma by nasal or oral administration.

EP 0 653 205 A1

INTRODUCTION TO THE INVENTION

The present invention is directed at aerosol formulations which are substantially free of chlorofluorocarbons (CFC's). More specifically, the present invention is directed at formulations substantially free of CFC's and having particular utility in medicinal applications, especially in metered dose pressurized inhalators (MDI's).

Metered dose inhalators have proven to be an effective method for delivering medicaments orally and nasally. They have been used extensively for delivering bronchodilating and steroidal compounds to asthmatics and may also be useful for delivering other compounds such as pentamidine and non-bronchodilator anti-inflammatory drugs. The rapid onset of activity of compounds administered in this manner and the absence of any significant side effects have resulted in a large number of compounds being formulated for administration via this route. Typically, the drug is delivered to the patient by a propellant system generally comprising one or more propellants which have the appropriate vapor pressure and which are suitable for oral or nasal administration. The more preferred propellant systems typically comprise propellant 11, propellant 12, propellant 114 or mixtures thereof. Often the vapor pressure of the propellant systems is adjusted by admixing a liquid excipient with the propellant.

However, propellants 11, 12 and 114 belong to a class of compounds known as chlorofluorocarbons, which have been linked to the depletion of ozone in the atmosphere. It has been postulated that ozone blocks certain harmful UV rays and that a decrease in the atmospheric ozone content will result in an increase in the incidence of skin cancer. In the 1970's certain steps were taken to reduce the CFC emissions from aerosols. Other propellants, such as hydrocarbons, were used, or the product was delivered in a different manner. Because CFC usage in medicinal applications is relatively low i.e. less than 1% of total CFC emissions, and because of the health benefits associated with metered dose inhalators, steps were not taken at that time to restrict the use of CFC propellants in metered dose inhalators.

However, continuing and more sophisticated ozone measurements have indicated that the earlier restrictions in CFC usage were insufficient and that additional, significant steps should be taken to drastically reduce CFC emissions. Recently, recommendations have been made that CFC production be virtually discontinued by the end of this century. As a result, it may not be possible to continue to use CFC propellants in the intermediate and long term. While some efforts have been made to use non-pressurized metered dose inhalators, many of these devices have not been completely successful. Many do not deliver uniform doses, are mechanically complex, do not provide the 100-200 doses per unit of current aerosol containers, are difficult for individuals to utilize, are bulky and/or cumbersome for the patients to use, particularly when they have an acute need for the medication.

As a result, there is a need for aerosol formulations substantially free of CFC's. Non-CFC propellants must meet several criteria for pressurized metered dose inhalators. They must be non-toxic, stable and non-reactive with the medicament and the other major components in the valve/actuator. One propellant which has been found to be suitable is $\text{CF}_3\text{-CH}_2\text{F}$, also known as Freon 134a, HFA 134a, HFC 134a or 1,1,1,2 tetrafluoroethane. However, the physical properties, i.e. vapor pressure, polarity, solubility, density and viscosity of HFC 134a differ from those of commonly used propellants. Propellant HFC 134a has a vapor pressure of 5.84×10^5 newton/meter² absolute (84.7 psia), which is too high for use in metered dose inhalators. In addition, commonly used surfactants may be insoluble in HFC 134a. Moreover, where the medicament is to be delivered as a solution, the medicament may not be readily soluble in this propellant. The density and polarity difference between HFC 134a and the previously used CFC propellant may result in a different delivery of the medicament when HFC 134a replaces a CFC propellant. The medicament may cream, settle or agglomerate in the non-CFC propellant even though this did not occur in the CFC propellant.

The use of HFA 134a previously has been disclosed for use in medicinal inhalators. European Patent Publication No. 0 372 777 is directed at medicinal aerosol formulations incorporating Freon 134a and an adjuvant having a higher polarity than the propellant. This publication lists several possible adjuvants and surfactants for use in combination with the propellant and the medicament.

International patent application No. WO 91/04011 discloses the combination of 1,1,1,2 tetrafluoroethane and a powdered medicament pre-coated with a non-perfluorinated surfactant prior to dispersing the powdered medicament in the propellant. Pages 6-7 of the publication list suitable surfactants for use with the propellant. A perfluorinated adjuvant optionally could be added. However, the pre-coating of the medicament may not be advantageous, since it adds an additional, complex step to the manufacturing process.

Research Disclosure No. 30161, May 1989 discloses that non-CFC propellants such as fluorohydrocarbons may be used in pressurized medicaments delivered directly to the lungs e.g. bronchodilators.

U.S. Patent No. 4,174,295 discloses the combination of HFC 134a with various chlorofluorocarbons and optionally a saturated hydrocarbon.

U.S. Patent No. 2,885,427 discloses the use of HFC-134a as an aerosol propellant.

U.S. Patent No. 3,261,748 discloses the use of HFC-134a for anesthesia.

5 U.S. Patent Nos. 4,129,603, 4,311,863, 4,851,595 and European Publication No. 379,793 also disclose the use of HFC-134a as an aerosol propellant.

However, the specific combinations noted above may not provide the desired solubility, stability, low toxicity, exact dosage, correct particle size (if suspension) and/or compatibility with commonly used valves assemblies of metered dose inhalers.

10

SUMMARY OF THE INVENTION

The present invention is directed at non-toxic formulations substantially free of CFC's, having improved stability and compatibility with the medicament and valve components and which are relatively easily
15 manufactured.

The present invention also is directed at formulations which may be utilized in present aerosol filling equipment with only relatively minor modifications and without pre-coating the medicament.

The invention includes an aerosol formulation comprising:

20 A. an effective amount of medicament; and

B. 1,1,1,2 tetrafluoroethane.

The formulation optionally may further comprise an excipient preferably selected from the group consisting of:

propylene glycol diesters of medium chain fatty acids;

triglyceride esters of medium chain fatty acids;

25 perfluorodimethylcyclobutane;

perfluorocyclobutane;

polyethylene glycol;

menthol;

lauroglycol;

30 diethylene glycol monoethylether;

polyglycolized glycerides of medium chain fatty acids;

alcohols;

eucalyptus oil;

short chain fatty acids;

35 and combinations thereof.

The formulation optionally may further comprise a surfactant. The surfactant preferably is selected from the group consisting of:

oleic acid;

sorbitan trioleate;

40 cetyl pyridinium chloride;

soya lecithin;

polyoxyethylene(20) sorbitan monolaurate;

polyoxyethylene(20) sorbitan monostearate;

polyoxyethylene(20) sorbitan monooleate;

45 polyoxypropylene-polyoxyethylene block copolymers;

polyoxyethylene (10) stearyl ether;

polyoxyethylene (2) oleyl ether;

polyoxypropylene-polyoxyethylene-ethylenediamine block copolymers;

castor oil ethoxylate; and combinations thereof.

50 The preferred liquid excipients are diethylene glycol monethylether, propylene glycol diesters of medium chain fatty acids, perfluorodimethylcyclobutane and polyethylene glycol.

The preferred surfactants are oleic acid; sorbitan trioleate, cetylpyridinium chloride; polyoxyethylene (20) sorbitan monolaurate; polyoxypropylene-polyoxyethylene block copolymers; soya lecithin; and polyoxypropylene-polyoxyethylene-ethylenediamine block copolymers; with oleic acid being particularly preferred.

55 The invention is of particular utility where the medicament is albuterol, mometasone furoate or beclomethasone dipropionate, and salts and clathrates thereof.

A formulation range comprises:

A. 1,1,1,2 tetrafluoroethane	25 - 99.99 wt %
B. medicament	0.01 - 1 wt %
C. excipient	0 - 75 wt %
D. surfactant (if present)	0 - 3 wt %

5

The present invention also is directed at a method of treating asthma in mammals comprising administering to a mammal in need of such treatment an effective amount of aerosol formulation comprising:

- 10 A. a medicament selected from the group comprising albuterol, mometasone furoate, beclomethasone dipropionate, and salts and clathrates thereof;
 B. 1,1,1,2 tetrafluoroethane; and
 C. optionally an excipient, preferably selected from the group consisting of:
 propylene glycol diesters of medium chain fatty acids;
 15 triglyceride esters of medium chain fatty acids;
 perfluorodimethylcyclobutane;
 perfluorocyclobutane;
 polyethylene glycol;
 menthol;
 20 lauroglycol;
 diethylene glycol monoethylether;
 polyglycolized glycerides of medium chain fatty acids;
 alcohols;
 short chain fatty acids;
 25 eucalyptus oil; and combinations thereof.
 A surfactant optionally is present. The surfactant preferably is selected from the group consisting of:
 oleic acid;
 sorbitan trioleate;
 cetyl pyridinium chloride;
 30 soya lecithin;
 polyoxyethylene (20) sorbitan monolaurate;
 polyoxyethylene (20) sorbitan monostearate;
 polyoxypropylene-polyoxyethylene block copolymers;
 polyoxyethylene (10) stearyl ether
 35 polyoxyethylene (2) oleyl ether
 polyoxyethylene-polyoxypropylene-ethylene diamine block copolymers
 castor oil ethoxylate; and combinations thereof.

DETAILED DESCRIPTION OF THE INVENTION

40

The formulations of the present invention all utilize propellant 134a in combination with the medicament, optionally a liquid excipient and optionally a surfactant. The excipient facilitates the compatibility of the medicament with the propellant and also lowers the discharge pressure to an acceptable range i.e. about $2.76 - 5.52 \times 10^5$ newton/meter² absolute (40 to 80 psia), preferably $3.45 - 4.83 \times 10^5$ newton/meter² absolute (50 to 70 psia). The excipient chosen must be non-reactive with the medicament, relatively non-toxic, and should have a vapor pressure below about 3.45×10^5 newton/meter² absolute (50 psia). As used hereinafter the term "medium chain fatty acids" refers to chains of alkyl groups terminating in a -COOH group and having 6-12 carbon atoms, preferably 8-10 carbon atoms. The term "short chain fatty acids" refers to chains of alkyl groups terminating in a -COOH group and having 4-8 carbon atoms. The term "alcohol" includes C₁-C₃ alcohols, such as methanol, ethanol and isopropanol. Among the preferred excipients are:

- propylene glycol diesters of medium chain fatty acids available under the tradename Miglyol 840 (from Hüls America, Inc. Piscataway, N.J.);
 triglyceride esters of medium chain fatty acids available under the tradename Miglyol 812 (from Hüls);
 55 perfluorodimethylcyclobutane available under the tradename Vertrel 245 (from E.I DuPont de Nemours and Co. Inc. Wilmington, Delaware);
 perfluorocyclobutane available under the tradename octafluoro cyclobutane (from PCR Gainesville, Florida);

polyethylene glycol available under the tradename PEG 400 (from BASF Parsippany, N.J.);
 menthol (from Pluess-Stauffer International Stamford, Connecticut);
 propylene glycol monolaurate available under the tradename lauroglycol (from Gattefossé Elmsford, N.Y.);

- 5 diethylene glycol monoethylether available under the tradename Transcutol (from Gattefossé);
 polyglycolized glyceride of medium chain fatty acids available under the tradename Labrafac Hydro WL 1219 (from Gattefossé);
 alcohols, such as ethanol, methanol and isopropanol;
 eucalyptus oil (available from Pluess-Stauffer International); and mixtures thereof.
- 10 A surfactant optionally may be added to lower the surface and interfacial tension between the medicament and the propellant. Where the medicament, propellant and excipient are to form a suspension, a surfactant may or may not be required. Where the medicament, propellant and excipient are to form a solution, a surfactant may or may not be necessary, depending in part on the solubility of the particular medicament and excipient. The surfactant may be any suitable, non-toxic compound which is non-reactive with the medicament and which substantially reduces the surface tension between the medicament, the excipient and the propellant and/or acts as a valve lubricant. Among the preferred surfactants are:
- 15 oleic acid available under the tradename oleic acid NF6321 (from Henkel Corp. Emery Group, Cincinnati, Ohio);
 cetylpyridinium chloride (from Arrow Chemical, Inc. Westwood, N.J.);
 soya lecithin available under the tradename Epikuron 200 (from Lucas Meyer Decatur, Illinois);
 20 polyoxyethylene (10) stearyl ether available under the tradename Brij 76 (from ICI);
 polyoxyethylene (2) oleyl ether available under the tradename Brij 92 (from ICI);
 polyoxyethylene-polypropylene-ethylenediamine block copolymer available under the tradename Tetronic 150 R1 (from BASF);
 25 polyoxyethylene(20) sorbitan monolaurate available under the tradename Tween 20 (from ICI Specialty Chemicals, Wilmington, Delaware);
 polyoxyethylene(20) sorbitan monostearate available under the tradename Tween 60 (from ICI);
 polyoxyethylene(20) sorbitan monooleate available under the tradename Tween 80 (from ICI);
 polyoxypropylene-polyoxyethylene block copolymers available under the tradenames Pluronic L-92,
 30 Pluronic L-121 and Pluronic F 68 (from BASF);
 castor oil ethoxylate available under the tradename Alkasurf CO-40 (from Rhone-Poulenc Mississauga Ontario, Canada); and mixtures thereof.

The medicaments of the present invention may include any pharmaceutically active compounds which are to be delivered by oral inhalation or nasally. Typical classes of compounds include bronchodilators, anti-inflammatory compounds, antihistamines, antiallergics analgesics, antitussives, anti-angina medications, 35 steroids, corticosteroids, vasoconstrictors and antibiotics. Specific compounds within these classes of compounds are albuterol, mometasone furoate, beclomethasone dipropionate isoproterenol, heparin, terbutaline, rimeterol, perbuterol, disodium cromoglycate, isoprenaline, adrenaline, pentamidine and ipratropium bromide. These compounds may be utilized either as the free base, as a salt, or as a clathrate depending upon the stability and solubility of the active compound in the specific formulation. Where clathrates are 40 utilized, P-11 and hexane clathrates are particularly preferred.

Where the active compound forms a suspension, the particle size should be relatively uniform, with substantially all the particles preferably ranging between about 0.1-25 microns, preferably 0.5-10 microns, more preferably 1-5 microns. Particles larger than 25 microns may be held up in the oropharyngeal cavity, 45 while particles smaller than about 0.5 micron preferably are not utilized, since they would be more likely to be exhaled and, therefore, not reach the lungs of the patient.

The formulations of the present invention may be filled into the aerosol containers using conventional filling equipment. Since propellant 134a may not be compatible with all elastomeric compounds currently utilized in present aerosol valve assemblies, it may be necessary to substitute other materials, such as 50 white buna rubber, or to utilize excipients and optionally surfactants which mitigate the adverse effects of propellant 134a on the valve components. One may optionally use an actuator device with a spacer to reduce force of the spray from an MDI.

To assure uniform dispersion of the active ingredient, the formulations typically will include the following components:

EP 0 653 205 A1

	Range (wt %)	Preferred Range (wt%)	Most Preferred Range (wt%)
Medicament	0.01 - 1	0.03 - 0.7	0.05 - 0.5
Propellant	25 - 99.99	50 - 99.97	50 - 99.95
Excipient(s)	0 - 75	0 - 50	0 - 50
Surfactant(s)	0 - 3	0 - 2	0 - 1

Depending on the particular application, the container may be charged with a predetermined quantity of formulation for single or multiple dosing. Typically, the container is sized for multiple-dosing, and, therefore, it is very important that the formulation delivered is substantially uniform for each dosing. For example, where the formulation is for bronchodilation, the container typically is charged with a sufficient quantity of the formulation for 200 charges.

Suitable suspensions may be screened in part by observing several physical properties of the formulation, i.e. the rate of particle agglomeration, the size of the agglomerates and the rate of particulate creaming/settling and comparing these to an acceptable standard. Suitable solutions may be screened by observing the solubility of the medicament over the entire recommended storage temperature range.

Suspensions of the present invention preferably may be prepared by either the pressure filling or cold filling procedures well-known in the art.

For metered dose inhalators, suspensions may be particularly preferred for efficacy and stability considerations.

Those skilled in the art may choose to add one or more preservative, buffer, antioxidant, sweetener and/or flavors or other taste masking agents depending upon the characteristics of the formulation.

Examples I - XXXII below further describe representative formulations of the present invention, some examples showing alternative formulations "A" and "B".

Example I	
Component	wt %
Albuterol	0.1
Vetrel 245	9.9
HFC-134a	90.0

Example II	
Component	wt %
Albuterol	0.5
Vetrel 245	49.9
HFC-134a	49.6

Example III	
Component	wt %
Albuterol	0.1
Oleic Acid	0.01
Miglyol 840	9.0
HFC 134a	90.89

EP 0 653 205 A1

5

Example IV	
Component	wt %
Albuterol	0.1
Tetronic 150 R1	0.1
Miglyol 840	9.8
HFC 134a	90.0

10

Example V	
Component	wt %
Albuterol	0.1
Pluronic L-121	0.1
Miglyol 840	9.8
HFC 134a	90.0

15

20

Example VI	
Component	wt %
Albuterol	0.1
Oleic acid	0.2
Transcutol	18.0
HFC 134a	81.7

25

30

Example VII		
Component	A wt %	B wt %
Albuterol	0.10	0.10
Oleic acid	0.01	0.01
Ethanol	30.00	15.00
HFC 134a	69.89	84.89

35

40

Example VIII		
Component	A wt%	B wt%
Albuterol sulfate	0.10	0.10
Oleic acid	0.01	0.01
Ethanol	30.00	15.00
HFC-134a	69.89	84.89

45

50

55

EP 0 653 205 A1

5

Example IX	
Component	wt %
Albuterol	0.1
Vetrel 245	17.0
Miglyol 840	9
HFC-134a	73.9

10

15

Example X	
Component	wt %
Albuterol	0.10
Oleic acid	0.01
Ethanol	10.00
Vetrel 245	9.90
HFC 134a	79.99

20

25

Example XI	
Component	wt %
Albuterol	0.1
Pluronic L-121	0.4
Vetrel 245	16.6
Miglyol 840	9
HFC-134a	73.9

30

35

Example XII	
Component	wt %
Albuterol	0.10
Pluronic L-121	0.90
Oleic acid	0.01
Miglyol 840	9.00
HFC 134a	89.99

40

45

Example XIII	
Component	wt %
Albuterol	0.10
Tetronic 150 R1	0.10
Oleic Acid	0.01
Miglyol 840	9.80
HFC-134a	89.99

50

55

EP 0 653 205 A1

Example XIV		
Component	A wt %	B wt %
Mometasone furoate	0.10	0.10
Oleic acid	0.01	0.01
Ethanol	30.00	15.00
HFC-134a	69.89	84.89

Example XV	
Component	wt %
Mometasone furoate	0.1
Oleic acid	0.2
Transcutol	18.0
HFC-134a	81.7

Example XVI	
Component	wt %
Mometasone furoate	0.1
Tween 20	0.1
Miglyol 840	9.8
HFC-134a	90.0

Example XVII	
Component	wt%
Mometasone furoate	0.1
Pluronic L-121	0.4
Miglyol 840	9.0
HFC-13a	90.5

Example XVIII	
Component	wt%
Mometasone furoate	0.1
Tetronic 150 R1	0.1
Miglyol 840	9.8
HFC-134a	90

EP 0 653 205 A1

Example XIX	
Component	wt %
Beclomethasone dipropionate	0.1
Oleic acid	0.01
Ethanol	5
HFC 134a	94.89

Example XX	
Component	wt %
Beclomethasone dipropionate P-11 clathrate	0.1
Oleic acid	.01
Miglyol 840	1.5
HFC-134a	98.39

Example XXI	
Component	wt %
Beclomethasone dipropionate hexane clathrate	0.1
Pluronic L121	.01
Miglyol 840	1.5
HFC-134a	98.3

Example XXII	
Component	wt%
Mometasone Furoate	0.1
HFC-134a	99.9

Example XXIII	
Component	wt%
Beclomethasone Dipropionate P-11 Clathrate	0.1
HFC-134a	99.9

Example XXIV	
Component	wt%
Mometasone Furoate	0.1
Tween 20	0.01
HFC-134a	99.89

EP 0 653 205 A1

Example XXV	
Component	wt%
Beclomethasone Dipropionate P-11 Clathrate	0.1
Tween 20	0.01
HFC-134a	99.89

Example XXVI	
Component	wt%
Mometasone furoate	0.1
Tween 20	0.01
Oleic Acid	0.0005
HFC-134a	99.8895

Example XXVII	
Component	wt%
Mometasone Furoate	0.1
Miglyol 840	9
Oleic Acid	0.005
Tetronic 150 R1	0.01
HFC-134a	90.885

Example XXVIII	
Component	wt%
Beclomethasone Dipropionate P-11 Clathrate	0.1
Miglyol 840	3
Oleic Acid	0.005
Pluronic L 121	0.01
HFC-134a	96.885

Example XXIX	
Component	wt %
Beclomethasone dipropionate	0.1
Oleic acid	0.2
Transcutol	5
HFC-134a	94.7

Example XXX	
Component	wt %
Beclomethasone dipropionate P-11 Clathrate	0.1
Pluronic L-121	0.1
Miglyol 840	1.5
HFC-134a	98.7

Example XXXI	
Component	wt%
Beclomethasone dipropionate	0.1
PEG 400	5
HFC-134a	94.9

Example XXXII	
Component	wt%
Beclomethasone Dipropionate P-11 Clathrate	0.1
Miglyol 840	1.5
HFC-134a	94.9

While the examples above have been directed at albuterol, albuterol sulfate, mometasone furoate, beclomethasone dipropionate and beclomethasone dipropionate clathrates, it is contemplated that other orally or nasally administered medicaments could be utilized. Similarly, it is contemplated that excipients and surfactants other than those exemplified may be utilized.

The descriptions of the foregoing embodiments of the invention have been presented for purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

Claims

1. An aerosol formulation comprising:

A. an effective amount of mometasone furoate;

B. 1,1,1,2-tetrafluoroethane;

C. optionally, one or more components selected from one or more of the following:

surfactants;

preservatives;

buffers;

antioxidants;

sweeteners; and

taste masking agents.

2. A formulation according to any preceding claim containing 0.01 to 1 percent by weight mometasone furoate.

3. A formulation according to claim 2 containing 0.03 to 0.7 percent by weight mometasone furoate.

4. A formulation according to claim 3 containing 0.05 to 0.5 percent by weight mometasone furoate.

EP 0 653 205 A1

5. A formulation according to any preceding claim wherein the mometasone furoate is a powder having a mean particle size of 1 to 5 microns.

6. A formulation according to any preceding claim following:

Component	Weight Percent
Mometasone furoate	0.01 - 1
1,1,1,2-Tetrafluoroethane	25 - 99.99
Excipient	0 - 75
Surfactant	0 - 3

7. A formulation according to Claim 6 containing the following:

Component	Weight Percent
Mometasone furoate	0.03 - 0.7
1,1,1,2-Tetrafluoroethane	50 - 99.97
Excipient	0 - 50
Surfactant	0 - 2

8. A formulation according to Claim 7 containing the following:

Component	Weight Percent
Mometasone furoate	0.05 - 0.5
1,1,1,2-Tetrafluoroethane	50 - 99.95
Excipient	0 - 50
Surfactant	0 - 1

9. A formulation according to any preceding claim for the treatment of asthma.

10. An aerosol dispersion of mometasone furoate in 1,1,1,2-tetrafluoroethane for the treatment of asthma.

11. Use of mometasone furoate in association with 1,1,1,2-tetrafluoroethane for the preparation of an aerosol pharmaceutical composition for oral and/or nasal administration to a patient suffering from asthma.

12. Use according to Claim 11 wherein the aerosol pharmaceutical composition comprises a surfactant.

13. Use according to Claim 11 wherein the aerosol pharmaceutical composition comprises an excipient.

14. Use of mometasone furoate in the manufacture of an aerosol pharmaceutical composition, said composition comprising as propellant 1,1,1,2-tetrafluoroethane, for the treatment by oral and/or nasal administration of asthma.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 1762

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.5)
D,Y	EP-A-0 372 777 (RIKER LABORATORIES, INC.) * the whole document * * page 2, line 4 - line 6 * ---	1-14	A61K9/72 A61K31/58
D,Y	WO-A-91 04011 (RIKER LABORATORIES, INC.) * the whole document * * page 15, line 35 - line 40; example 2 * ---	1-14	
Y	'the merck index, eleventh eddition' 1989, MERCK & CO., INC., RAHWAY, N.J. (US) * page 982, column 1; example 6151 * ---	1-14	
Y	CHEMICAL ABSTRACTS, vol. 111, no. 11, 11 September 1989, Columbus, Ohio, US; abstract no. 90641X, H. SAKONJO ET AL. 'general pharmacological effects of mometasone furoate. II. effects on EEG, respiration, and the cardiovascular system.' page 104 ;column 1 ; * abstract * & YONAGO IGAKU ZASSHI, vol.40, no.3, 1989, JP pages 348 - 354 -----	1-14	
			TECHNICAL FIELDS SEARCHED (Int.Cl.5)
			A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 20 March 1995	Examiner Benz, K
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	